Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.18 | N/A | +23.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.18 | N/A | +23.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's direction. They emphasized their commitment to growth and innovation.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts to enhance product offerings and market reach.
Veracyte's earnings report showed a positive surprise in EPS, which contributed to a 1.37% increase in stock price. The lack of revenue figures may leave some investors wanting more clarity, but the EPS beat suggests the company is managing its costs effectively. Management's optimistic tone indicates potential for future growth, although specific guidance was not offered.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SLB Limited
Jul 20, 2018